Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "lymphoma cell" wg kryterium: Temat


Wyświetlanie 1-9 z 9
Tytuł:
Cytopathology of canine lymphomas (100 cases)
Autorzy:
Sapierzynski, R.
Micun, J.
Jagielski, D.
Jurka, P.
Powiązania:
https://bibliotekanauki.pl/articles/31296.pdf
Data publikacji:
2010
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
cytopathology
canine lymphoma
lymphoma
dog
malignant lymphoma
tumour
animal disease
occurrence
T cell
biopsy
Opis:
Malignant lymphoma is one of the most common malignant tumours occurring in dogs. Fine needle aspiration biopsy (FNAB) is an excellent, specific diagnostic procedure used to assess pathological processes in lymph nodes. The aim of the present study was to conduct a cytopathological analysis of lymphoma in dogs and to analyse some epidemic aspects of occurrence of lymphoma in 100 dogs using Giemsa stained slides. Samples were obtained by fine needle aspiration biopsy, fine needle non-aspiration biopsy, lymph node impression smears and by examination of body cavity effusions. The determination of the type and subtype of tumour was made on the basis of the updated Kiel classification adopted for dogs. Based on cytopathological analysis, the lymphoma was diagnosed in 100 dogs: 44 were female and 56 male. The animals’ age ranged from 1.5 year to 15 years (median: 7.5 years), the animals were of different breeds (72% of all dogs belonged to 28 different breeds) and crossbreeds (28%). In 29% of dogs the regional or general lymphadenomegaly was the only clinical sign observed, in remaining cases (71%) at least one abnormality connected to lymphoma was found. Among all diagnosed lymphomas, high-grade lymphomas were more prevalent (86% of all cases) than low-grade lymphomas (14% of all cases). The possibility of boxers having a predisposition to T cell lymphoma development could be also suspected.
Źródło:
Polish Journal of Veterinary Sciences; 2010, 13, 4
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Diffuse large B cell lymphoma of the oral cavity - case report
Autorzy:
Gaweda, A.
Jach, E.
Wojciechowicz, J.
Sokolowska, B.
Tomaszewski, T.
Powiązania:
https://bibliotekanauki.pl/articles/3452.pdf
Data publikacji:
2014
Wydawca:
Instytut Medycyny Wsi
Tematy:
diffuse large B cell lymphoma
oral cavity
palate
ulceration
pathological change
patient
Źródło:
Journal of Pre-Clinical and Clinical Research; 2014, 08, 1
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunohistochemical study of expression of immunoglobulins in canine B-cell lymphomas
Autorzy:
Sokolowska, J.
Micun, J.
Zabielska, K.
Malicka, E.
Lechowski, R.
Powiązania:
https://bibliotekanauki.pl/articles/31685.pdf
Data publikacji:
2010
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
immunohistochemistry
expression
immunoglobulin
dog
B cell
lymphoma
tumour
neoplastic cell
immunoglobulin light chain
cancer
Opis:
Nineteen canine lymphomas were included in this study. Tumors were classified according to the updated Kiel classification adapted for canine lymphomas by Fournel-Fleury et al. Immunoglobulin light chains (κ and λ) and IgM and IgG expression were determined by immunohistochemical method. In all examined cases neoplastic cells were positive for one of the immunoglobulin light chains. Expression of λ light chains and κ light chains was observed in 18/19 and 1/19 tumors, respectively. In the majority of neoplastic cells in each examined specimen this reaction had a membranous pattern (sκ/sλ). In all examined cases the presence of immunoglobulin light chains was also observed in the cytoplasm of some neoplastic cells (cκ/cλ). These cells were usally rare and never constituted a dominant population. The expression of immunoglobulin was found in 13/19 cases. Most lymphomas were sIgM positive (11/13 cases). In one case expression of IgG was found, and in another lymphoma two populations of neoplastic cells with different expression of examined immunoglobulins (cells with IgM+ and IgG+ phenotypes) were observed. The reaction also had a membranous pattern. The cells containing cytoplasmic immunoglobulins were rare, and in most cases were of the same type as the surface immunoglobulins. Our study has confirmed that canine lymphomas are a monoclonal proliferation of B-cells usually expressing immunoglobulin λ light chains and that the vast majority of tumors deriving from B-cells express IgM. Our study also indicates a possibility of occurence of biclonal lymphomas in canine species.
Źródło:
Polish Journal of Veterinary Sciences; 2010, 13, 4
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Lethal acute liver failure in a 60 y/o female patient with AILD III (Ann Arbor) T-cell lymphoma in remission state - case report
Autorzy:
Kuczynska, M.
Dziaduch, E.
Grzywa-Celinska, A.
Lachowska-Kotowska, P.
Mosiewicz, J.
Powiązania:
https://bibliotekanauki.pl/articles/3662.pdf
Data publikacji:
2014
Wydawca:
Instytut Medycyny Wsi
Tematy:
acute liver failure
liver function
female patient
hepatic cirrhosis
T cell
lymphoma cell
remission state
Źródło:
Journal of Pre-Clinical and Clinical Research; 2014, 08, 1
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Practical aspects of immunocytochemistry in canine lymphomas
Autorzy:
Sapierzynski, R.
Powiązania:
https://bibliotekanauki.pl/articles/32144.pdf
Data publikacji:
2010
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
immunocytochemistry
canine lymphoma
lymphoma
dog
cytology
immunophenotype
tumour cell
biopsy
diagnosis
Kiel classification
Lennert classification zob.Kiel classification
Opis:
The aim of this study was to evaluate the utility of immunocytochemistry in a standard veterinary practice and to determine the immunophenotype of tumor cells in cases of multicentric lymphoma in dogs by immunocytochemical analysis of fine-needle biopsy specimens. The study was performed on cytological samples collected from 54 dogs, in which multicentric lymphoma was recognised based on clinical data, cytology or cytology and histology, and follow-up information. Diagnosis of lymphoma was established according to the updated Kiel classification. Immunocytochemical assays were conducted using commercially available antibodies to the pan T-lymphocyte marker CD3 and B cell antigen receptor complex CD79 alpha. Among all animals examined B cell lymphoma was recognized in 42/54 (77.8%) of cases, while in the remaining 12/54 (22.2%) of dogs T cell lymphoma was recognized. In 11 animals with lymphoma recognized cytologically, in which an entire lymph node was obtained for histology, the results of routine cytology and immunocytochemistry fully corresponded with findings revealed by histology and immunohistochemistry. Immunocytochemistry can be successfully conducted in smears stored at room temperature for 24 hours without changes of staining results. It can be stated that application of standard cytopathological assessment in connection with immunocytochemistry of lymph nodes samples collected from dogs with lymphoma is a method of choice for establishing final diagnosis, and avoids the need for reexamination or collection of tissue samples for histopathology and immunohistochemistry during surgical procedures in ambiguous cases.
Źródło:
Polish Journal of Veterinary Sciences; 2010, 13, 4
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Primary cutaneous B-cell lymphoma located on the face and hard palate
Autorzy:
Brzeziński, Piotr
Chiriac, Anca
Budurca, Radu
Chiriac, Anca E.
Pinteala, Tudor
Ivan, Luminita
Foia, Liliana
Powiązania:
https://bibliotekanauki.pl/articles/1065379.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
B-cell lymphoma
face and hard palate lymphoma
non-Hodgkin lymphoma
Opis:
Introduction: Primary cutaneous B-cell lymphomas represent primary cutaneous lymphomas. The World Health Organization-European Organization for Research and Treatment of Cancer defines primary cutaneous B-cell limphomas as malignant lymphomas that are confined to the skin at presentation after complete staging procedures. Case report: We report a case of a woman with a cutaneous nodular B-cell lymphoma of the face, with very slow evolution that could easily be misdiagnosed. The patient had two non-ulcerated nodules on the left part of the face. A histological examination on both pieces following surgical excision showed a diffuse infiltrate of atypical B cells. The patient was subsequently directed to the Oncology Department for further investigation, but she died 24 hours afterwards due to one of the acute possible complications of the disease: pulmonary embolism. Conclusion: Cutaneous B-cell lymphoma is an unusual and rare skin neoplasm with a great range of clinical presentations and this is an alarm sign for apparent common skin lesion.
Źródło:
OncoReview; 2014, 4, 3; A113-116
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Quality of life patients treated with rituximab intravenous vs. subcutaneous in B-cell lymphomas: results from outpatient Hematooncology Clinic in Lodz
Autorzy:
Witkowska, Magdalena
Witkowska, Sonia
Klimczak, Marika
Frydecka, Anna
Witkowski, Michał
Smolewski, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/2047211.pdf
Data publikacji:
2021-07-14
Wydawca:
Medical Education
Tematy:
Rituximab
quality of life
anti CD20
B-cell NHL
lymphoma
Opis:
Introduction: Nowadays, rituximab is available both as intravenous (IV) and subcutaneous (SC) formulations. The aim of this study is to compare quality of life (QOL) of patients treated in Hematooncology Clinic in Lodz with B-cell nonHodgkin lymphoma (B-NHL) treated with rituximab IV and SC. Material and Methods: In 50 adult patients with B-NHL diagnosis we assessed QOL by three different questionnaries (EORTC QLQ-C30, FACT/ GOG-NTx and EQ-5D). We compared it between patients treated with rituximab IV and SC. Results: In comparison of general condition in EQ-5D-3L and EORTC QLQ-C30 questionnaire patients treated with rituximab SC felt statistically better than with IV administration (p<0.01). In SC group general health was evaluated for 72 while in IV for only 58,1. According to FACT/GOG-NTx questionnaire SC group had significantly better physical well-being. In SC group we observed statistically more complete responses (CR) 21 (88%) versus 17 (65%) in IV group. Moreover, trend was observed in emotional well-being in favor of SC treatment. Discussion: In our study we observed for the first time in the literature statistical difference in frequency of vomiting, nausea, and lack of appetite mentioned from our patients in questionnarie. It is very important that this findings were not published in any other study comparing SC and IV route od administration. Also looking at economic side of SC administration, this type of dosing. As a result it should be preferred form for B-cell lymphoma patients.
Źródło:
OncoReview; 2021, 11, 2; 33-39
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The stimulation and inhibition of T cell proliferation by Helicobacter pylori components
Autorzy:
Chmiela, M
Lelwala-Guruge, J.A.
Wadstrom, T.
Rudnicka, W.
Powiązania:
https://bibliotekanauki.pl/articles/69409.pdf
Data publikacji:
1996
Wydawca:
Polskie Towarzystwo Fizjologiczne
Tematy:
polyacrylamide gel electrophoresis
blood leucocyte
sodium dodecyl sulphate
horse
stimulation
macrophage
chronic active gastritis
Helicobacter pylori
antibody
gastric carcinoma
cell proliferation
peripheral blood
ulcer
plasma cell
lymphocyte
infiltration
inhibition
gastric lymphoma
Źródło:
Journal of Physiology and Pharmacology; 1996, 47, 1
0867-5910
Pojawia się w:
Journal of Physiology and Pharmacology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Z-BEAM jako nowy reżim przygotowawczy w przeszczepianiu komórek krwiotwórczych – prezentacja przypadku
Z-BEAM: a novel conditioning regimen in hematopoietic stem cell transplantation. Case report
Autorzy:
Krzysztof, Gawroński
Piotr, Rzepecki
Sylwia, Oborska
Powiązania:
https://bibliotekanauki.pl/articles/1031078.pdf
Data publikacji:
2012
Wydawca:
Medical Communications
Tematy:
chłoniaki nieziarnicze
conditioning
hematopoietic stem cell transplantation
ibritumomab tiuxetan
ibrytumomab tiuksetanu
kondycjonowanie
non-Hodgkin lymphoma
przeszczepianie krwiotwórczych komórek macierzystych
radioimmune therapy
radioimmunoterapia
rituximab
rytuksymab
Opis:
Low-grade lymphomas pose a considerable therapeutic problem, as they yield to treatment very reluctantly. Not infrequently we are faced with resistance to chemotherapy. This type of lymphomas are usually seen in persons of middle or advanced age, rarely in people under 30. Due to the presence of CD20+ receptor on cell membranes of lymphoma originating from B-cells, monoclonal antibody anti-CD20+ (rituximab) has been introduced to the therapy. This has certainly resulted in improved outcomes. Of value in consolidation treatment of low-grade lymphomas is also autologous or allogenic hematopoietic cell transplantation (autoHSCT, alloHSCT). As escalation of dose of cytostatics as myeloablative treatment prior to autoHSCT or alloHSCT may not guarantee total eradication of residual lymphoma cells, research focuses on treatment modalities which might improve late outcomes in this tumor type. In this setting useful proved radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin). Zevalin combined with high-dose chemotherapy can be used now as a component of myeloablative treatment prior to autoHSCT. Reduced intensity conditioning (RIC) contributes to reduced mortality associated with standard conditioning protocol administered prior to transplantation, but may facilitate disease recurrence. Radioimmunotherapy using ibritumomab may reduce recurrence rate and, as a conditioning measure, may be initiated on the outpatient setting, prior to admission to bone marrow transplantation center. Labeling of antibodies and their application must take place at a Nuclear Medicine Unit, observing all necessary precautions and regulations concerning radiation protection. Administration of ibritumomab is preceded by application of two doses of rituximab: 250 mg/m2, 7 days and 4 hours prior to the RIT procedure. The dose of rituximab administered one week before, according to recommended protocol of ibritumomab use, initially preceded dosimetry (administration of indium-labeled antibodies).
Chłoniaki o niskim stopniu złośliwości stanowią istotny problem terapeutyczny, gdyż bardzo trudno poddają się leczeniu. Nierzadko spotykamy się z opornością na chemioterapię. Zazwyczaj chłoniaki tego typu występują u ludzi w średnim lub starszym wieku. Rzadziej u chorych młodszych (poniżej 30. roku życia). W związku z obecnością ekspresji receptora CD20+ na błonach komórkowych komórek chłoniaka wywodzącego się z komórek B zaczęto stosować poza chemioterapią przeciwciało monoklonalne antyCD20+ (rytuksymab). Oczywiście udało się dzięki temu przeciwciału poprawić efekty terapeutyczne. Swoją wartość w leczeniu konsolidującym chłoniaków o niskim stopniu złośliwości ma też przeszczepienie autologicznych bądź alogenicznych komórek krwiotwórczych (autoHSCT i alloHSCT). Ponieważ eskalacja dawek cytostatyków jako leczenie mieloablacyjne przed autoHSCT i alloHSCT może nie zapewniać pełnej eradykacji resztkowych komórek chłoniaka, poszukuje się metod terapeutycznych, które poprawiłyby odległe efekty leczenia tego typu nowotworów. Tutaj swoje miejsce znalazła radioimmunoterapia za pomocą 90Y-ibrytumomabu tiuksetanu (Zevalin). Zevalin wraz z wysokodawkową chemioterapią można obecnie stosować jako jeden ze składników leczenia mieloablacyjnego przed autoHSCT. Kondycjonowanie o zredukowanej intensywności (RIC) zmniejsza śmiertelność związaną ze schematem przygotowawczym stosowanym przed podaniem przeszczepu, ale mogą zdarzać się nawroty choroby. Radioimmunoterapia z zastosowaniem ibrytumomabu jest procedurą, która może zmniejszyć częstość nawrotów choroby i może być jako kondycjonowanie rozpoczynana ambulatoryjnie, zanim chory zostanie przyjęty do ośrodka przeszczepiania szpiku. Samo przygotowanie (znakowanie) przeciwciał i ich podanie musi się odbyć w Zakładzie Medycyny Nuklearnej, z zachowaniem niezbędnych środków ochrony radiologicznej. Podanie ibrytumomabu poprzedza infuzja dwóch dawek rytuksymabu: 250 mg/m2, 7 dni i 4 godziny przed samą procedurą RIT. Dawka rytuksymabu podana tydzień wcześniej, zgodnie z zalecanym schematem podania ibrytumomabu, pierwotnie poprzedzała dozymetrię (podanie przeciwciała znakowanego indem).
Źródło:
Current Gynecologic Oncology; 2012, 10, 2; 165-175
2451-0750
Pojawia się w:
Current Gynecologic Oncology
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-9 z 9

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies